

Carlos A Torres-Cabala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1159392/publications.pdf>

Version: 2024-02-01

174
papers

7,250
citations

94433

37
h-index

62596

80
g-index

176
all docs

176
docs citations

176
times ranked

9690
citing authors

#	ARTICLE	IF	CITATIONS
1	Loss of PTEN Promotes Resistance to T Cellâ€Mediated Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 202-216.	9.4	1,158
2	HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. <i>Cancer Cell</i> , 2005, 8, 143-153.	16.8	843
3	The Morphologic Spectrum of Kidney Tumors in Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) Syndrome. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1578-1585.	3.7	361
4	EVALUATION AND MANAGEMENT OF RENAL TUMORS IN THE BIRT-HOGG-DUBÃ‰ SYNDROME. <i>Journal of Urology</i> , 2005, 173, 1482-1486.	0.4	260
5	Hereditary Leiomyomatosis and Renal Cell Cancer: A Syndrome Associated With an Aggressive Form of Inherited Renal Cancer. <i>Journal of Urology</i> , 2007, 177, 2074-2080.	0.4	235
6	High Frequency of Somatic Frameshift BHD Gene Mutations in Birt-Hogg-DubÃ‰Associated Renal Tumors. <i>Journal of the National Cancer Institute</i> , 2005, 97, 931-935.	6.3	213
7	Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. <i>Modern Pathology</i> , 2009, 22, 1446-1456.	5.5	196
8	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 158-176.	1.3	186
9	Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 6958-6963.	7.1	165
10	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 508-515.	0.7	138
11	Autoimmune dermatologic toxicities from immune checkpoint blockade with antiâ€PD-1 antibody therapy: a report on bullous skin eruptions. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 688-696.	1.3	126
12	Expression of Birtâ€Hoggâ€DubÃ‰ gene mRNA in normal and neoplastic human tissues. <i>Modern Pathology</i> , 2004, 17, 998-1011.	5.5	124
13	Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. , 2018, 6, 14.		118
14	EARLY ONSET HEREDITARY PAPILLARY RENAL CARCINOMA: GERMLINE MISSENSE MUTATIONS IN THE TYROSINE KINASE DOMAIN OF THE MET PROTO-ONCOGENE. <i>Journal of Urology</i> , 2004, 172, 1256-1261.	0.4	115
15	Cutaneous Metastases of Malignant Melanoma: A Clinicopathologic Study of 192 Cases With Emphasis on the Morphologic Spectrum. <i>American Journal of Dermatopathology</i> , 2010, 32, 129-136.	0.6	97
16	Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 5553-5563.	7.0	96
17	Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features. <i>American Journal of Dermatopathology</i> , 2017, 39, 121-129.	0.6	96
18	TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. <i>Modern Pathology</i> , 2021, 34, 710-719.	5.5	90

#	ARTICLE	IF	CITATIONS
19	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. <i>Clinical Cancer Research</i> , 2018, 24, 4416-4428.	7.0	89
20	HER2/neu expression in extramammary Paget disease: a clinicopathologic and immunohistochemistry study of 47 cases with and without underlying malignancy. <i>Journal of Cutaneous Pathology</i> , 2009, 36, 729-733.	1.3	77
21	NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 522-536.	4.9	69
22	Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma. <i>Modern Pathology</i> , 2013, 26, 1153-1160.	5.5	67
23	Immunohistochemical Expression of S100A6 in Cellular Neurothekeoma: Clinicopathologic and Immunohistochemical Analysis of 31 Cases. <i>American Journal of Dermatopathology</i> , 2009, 31, 419-422.	0.6	62
24	Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. <i>International Journal of Dermatology</i> , 2014, 53, 376-384.	1.0	62
25	EBV-negative Aggressive NK-cell Leukemia/Lymphoma. <i>American Journal of Surgical Pathology</i> , 2017, 41, 67-74.	3.7	59
26	Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta ($\gamma\delta$) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous $\gamma\delta$ T-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2017, 41, 204-215.	3.7	57
27	Melanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature. <i>Modern Pathology</i> , 2014, 27, 1468-1478.	5.5	54
28	Proteomic Identification of New Biomarkers and Application in Thyroid Cytology. <i>Acta Cytologica</i> , 2006, 50, 518-528.	1.3	50
29	The In vitro and In vivo Effects of Re-Expressing Methylated von Hippel-Lindau Tumor Suppressor Gene in Clear Cell Renal Carcinoma with 5-Aza-2'-deoxycytidine. <i>Clinical Cancer Research</i> , 2004, 10, 7011-7021.	7.0	49
30	Molecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2012, 31, 267-273.	1.6	48
31	The differential diagnosis of CD8-positive (cytotoxic T) lymphomatoid papulosis. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 88-100.	1.3	48
32	Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. <i>Clinical Cancer Research</i> , 2017, 23, 2093-2104.	7.0	48
33	Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy—Report of 2 patients. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1080-1086.	1.3	48
34	Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America. <i>Clinical and Translational Oncology</i> , 2017, 19, 1478-1488.	2.4	46
35	Diagnostic Utility and Comparative Immunohistochemical Analysis of MITF-1 and SOX10 to Distinguish Melanoma In Situ and Actinic Keratosis. <i>American Journal of Dermatopathology</i> , 2014, 36, 124-130.	0.6	43
36	Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. <i>Human Pathology</i> , 2015, 46, 1101-1110.	2.0	43

#	ARTICLE	IF	CITATIONS
37	Fine-needle aspiration of a Xp11.2 translocation/TFE3 fusion renal cell carcinoma metastatic to the lung: Report of a case and review of the literature. <i>Diagnostic Cytopathology</i> , 2006, 34, 751-756.	1.0	42
38	Metastatic Atypical Fibroxanthoma. <i>American Journal of Dermatopathology</i> , 2015, 37, 455-461.	0.6	40
39	Loss of $\langle scp \rangle$ CD30 $\langle /scp \rangle$ expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 1161-1166.	1.3	40
40	Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 764-773.	1.3	38
41	Role of Chromogenic in Situ Hybridization (CISH) in the Evaluation of HER2 Status in Breast Carcinoma: Comparison with Immunohistochemistry and Fish. <i>International Journal of Surgical Pathology</i> , 2005, 13, 343-351.	0.8	35
42	Clinicopathological and molecular study of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 1121-1130.	1.3	34
43	Positive Sentinel Node in Sebaceous Carcinoma of the Eyelid. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2011, 27, e4-e6.	0.8	33
44	Ambiguous Melanocytic Tumors in a Tertiary Referral Center. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1783-1796.	3.7	31
45	p40 Is More Specific Than p63 for the Distinction of Atypical Fibroxanthoma From Other Cutaneous Spindle Cell Malignancies. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1102-1110.	3.7	31
46	A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma. <i>BMC Cancer</i> , 2018, 18, 1274.	2.6	31
47	NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1460-1467.	4.9	30
48	Expression of Hypoxia Inducible Factor-1 α and 2 α in Genetically Distinct Early Renal Cortical Tumors. <i>Journal of Urology</i> , 2006, 175, 1908-1914.	0.4	28
49	Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 326-328.	1.3	28
50	Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 1075-1079.	1.3	27
51	Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14 ⁺ and CD16 ⁺ monocytes driving an innate immune response. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 627-636.	1.3	27
52	Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 504-507.	1.3	25
53	B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. <i>Clinical Cancer Research</i> , 2019, 25, 3455-3467.	7.0	24
54	Primary Cutaneous Small- to Medium-Sized CD4+ Pleomorphic T-Cell Lymphoma. <i>American Journal of Clinical Dermatology</i> , 2011, 12, 1.	6.7	23

#	ARTICLE	IF	CITATIONS
55	Indeterminate dendritic cell neoplasm of the skin: A case report and review of the literature. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 958-963.	1.3	23
56	Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma. <i>Cancers</i> , 2019, 11, 2031.	3.7	23
57	Update on eighth edition American Joint Committee on Cancer classification for Merkel cell carcinoma and histopathological parameters that determine prognosis. <i>Journal of Clinical Pathology</i> , 2019, 72, 337-340.	2.0	23
58	PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1680-1691.	4.1	22
59	Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy. <i>Cancers</i> , 2019, 11, 754.	3.7	21
60	Update on eighth edition American Joint Committee on Cancer classification for cutaneous melanoma and overview of potential pitfalls in histological examination of staging parameters. <i>Journal of Clinical Pathology</i> , 2019, 72, 265-270.	2.0	21
61	Differential Expression of S100C in Thyroid Lesions. <i>International Journal of Surgical Pathology</i> , 2004, 12, 107-115.	0.8	20
62	Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma. <i>Clinical and Translational Oncology</i> , 2019, 21, 1127-1134.	2.4	20
63	Syringocystadenocarcinoma Papilliferum With Transition to Areas of Squamous Differentiation. <i>American Journal of Dermatopathology</i> , 2012, 34, 428-433.	0.6	19
64	Immunophenotypic shift of CD4 and CD8 antigen expression in primary cutaneous T-cell lymphomas: a clinicopathologic study of three cases. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 51-57.	1.3	19
65	Pigmented extramammary Paget disease of the thigh mimicking a melanocytic tumor: report of a case and review of the literature. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 529-535.	1.3	19
66	Molecular characteristics and potential therapeutic targets in Merkel cell carcinoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 382-390.	2.0	19
67	Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. <i>Modern Pathology</i> , 2020, 33, 496-513.	5.5	19
68	GNAQ mutation in a patient with metastatic mucosal melanoma. <i>BMC Cancer</i> , 2014, 14, 516.	2.6	18
69	Panniculitis With Necrotizing Granulomata in a Patient on BRAF Inhibitor (Dabrafenib) Therapy for Metastatic Melanoma. <i>American Journal of Dermatopathology</i> , 2015, 37, e96-e99.	0.6	18
70	Emerging clinical applications of selected biomarkers in melanoma. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2015, 8, 35.	1.8	18
71	BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. <i>Human Pathology</i> , 2016, 50, 79-89.	2.0	18
72	Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 786-790.	1.3	18

#	ARTICLE	IF	CITATIONS
73	Lymphomatoid Granulomatosis With Involvement of the Hard Palate: A Case Report. <i>Journal of Oral and Maxillofacial Surgery</i> , 2008, 66, 2161-2163.	1.2	17
74	Histological Features Associated With Vemurafenib-Induced Skin Toxicities. <i>American Journal of Dermatopathology</i> , 2014, 36, 557-561.	0.6	17
75	Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 7585-7593.	7.0	17
76	Post-radiation vascular lesions of the breast. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 52-58.	1.3	17
77	Pathology-based Biomarkers Useful for Clinical Decisions in Melanoma. <i>Archives of Medical Research</i> , 2020, 51, 827-838.	3.3	17
78	Detection of Human Papillomavirus in Multiple Eccrine Poromas in a Patient With Chronic Graft-vs-Host Disease and Immunosuppression. <i>Archives of Dermatology</i> , 2010, 147, 120.	1.4	16
79	Somatic rearrangement of the TP63 gene preceding development of mycosis fungoides with aggressive clinical course. <i>Blood Cancer Journal</i> , 2014, 4, e253-e253.	6.2	16
80	Detection of mitotic figures and $G2$+ tumor nuclei with histone markers correlates with worse overall survival in patients with Merkel cell carcinoma. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 846-852.	1.3	16
81	Level of tumor-infiltrating lymphocytes and density of infiltrating immune cells in different malignancies. <i>Biomarkers in Medicine</i> , 2019, 13, 1481-1491.	1.4	16
82	Impact of the 2009 (7th Edition) AJCC Melanoma Staging System in the Classification of Thin Cutaneous Melanomas. <i>BioMed Research International</i> , 2013, 2013, 1-7.	1.9	15
83	High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients. <i>Melanoma Research</i> , 2017, 27, 24-31.	1.2	15
84	Melanoma With Loss of BAP1 Expression in Patients With No Family History of BAP1-Associated Cancer Susceptibility Syndrome: A Case Series. <i>American Journal of Dermatopathology</i> , 2019, 41, 167-179.	0.6	14
85	T-Cell Repertoire in Combination with T-Cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2146-2156.e4.	0.7	14
86	Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 539-544.	1.3	13
87	Differential expression of CCR4 in primary cutaneous gamma/delta (Î³Î´) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy. <i>Journal of Dermatological Science</i> , 2018, 89, 88-91.	1.9	13
88	H3K79me3 and H3T80ph is a Novel Histone Dual Modification and a Mitotic Indicator in Melanoma. <i>Journal of Skin Cancer</i> , 2012, 2012, 1-9.	1.2	12
89	A case of indeterminate dendritic cell tumor presenting with leonine facies. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 158-163.	1.3	12
90	Immunophenotypic Shifts in Primary Cutaneous Î³Î´ T-Cell Lymphoma Suggest Antigenic Modulation. <i>American Journal of Surgical Pathology</i> , 2017, 41, 431-445.	3.7	12

#	ARTICLE	IF	CITATIONS
91	PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2019, 11, 695.	3.7	12
92	Use of clinical next-generation sequencing to identify melanomas harboring <i>SMARCB1</i> mutations. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 308-317.	1.3	11
93	HTLV-1-associated infective dermatitis demonstrates low frequency of FOXP3-positive T-regulatory lymphocytes. <i>Journal of Dermatological Science</i> , 2015, 77, 150-155.	1.9	11
94	Proliferation indices correlate with diagnosis and metastasis in diagnostically challenging melanocytic tumors. <i>Human Pathology</i> , 2016, 53, 73-81.	2.0	11
95	Concomitant Cutaneous Langerhans Cell Histiocytosis and Leukemia Cutis. <i>American Journal of Dermatopathology</i> , 2017, 39, 388-392.	0.6	11
96	Diagnostic utility of <i>PRAME</i> in distinguishing proliferative nodules from melanoma in giant congenital melanocytic nevi. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 1410-1415.	1.3	11
97	Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. <i>International Journal of Dermatology</i> , 2019, 58, 1045-1052.	1.0	11
98	Severe architectural disorder is a potential pitfall in the diagnosis of small melanocytic lesions. <i>Journal of Cutaneous Pathology</i> , 2010, 37, 860-865.	1.3	10
99	Unusual cutaneous metastatic carcinoma. <i>Annals of Diagnostic Pathology</i> , 2019, 43, 151399.	1.3	10
100	BAP-1 Expression Status by Immunohistochemistry in Cellular Blue Nevus and Blue Nevus-like Melanoma. <i>American Journal of Dermatopathology</i> , 2020, 42, 313-321.	0.6	10
101	Giemsa is the optimal counterstain for immunohistochemical detection of <i>BRAF V600E</i> mutation status in pigmented melanomas. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 722-724.	1.3	9
102	Measurement of Tumor Thickness in Cutaneous Squamous Cell Carcinomas: Do the Different Methods Provide Better Prognostic Data?. <i>American Journal of Dermatopathology</i> , 2020, 42, 337-342.	0.6	9
103	Cutaneous metastasis from anaplastic thyroid carcinoma exhibiting exclusively a spindle cell morphology. A case report and review of literature. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 252-257.	1.3	8
104	Detection of Merkel Cell Polyoma Virus and Beta Human Papillomavirus in Multiple Eccrine Poromas in a Patient With Acute Leukemia Treated With Stem Cell Transplant. <i>American Journal of Dermatopathology</i> , 2017, 39, 489-491.	0.6	8
105	Clinical significance of <i>BRAF V600E</i> mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma. <i>Human Pathology</i> , 2017, 59, 48-54.	2.0	8
106	Intratumoral and peritumoral lymphovascular invasion detected by D2-40 immunohistochemistry correlates with metastasis in primary cutaneous Merkel cell carcinoma. <i>Human Pathology</i> , 2018, 77, 98-107.	2.0	8
107	<i>BCAT1</i> and miR-2504: novel methylome signature distinguishes spindle/desmoplastic melanoma from superficial malignant peripheral nerve sheath tumor. <i>Modern Pathology</i> , 2019, 32, 338-345.	5.5	8
108	Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 954-959.	1.3	8

#	ARTICLE	IF	CITATIONS
109	Prognostic significance of acral lentiginous histologic type in T1 melanoma. <i>Modern Pathology</i> , 2021, 34, 572-583.	5.5	8
110	Gamma/Delta Phenotype in Primary Cutaneous T-cell Lymphomas and Lymphoid Proliferations. <i>Surgical Pathology Clinics</i> , 2021, 14, 177-194.	1.7	8
111	Prognostic Significance of Subungual Anatomic Site in Acral Lentiginous Melanoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 943-952.	2.5	8
112	Cutaneous epithelioid angiomatous nodule of the chest wall with expression of estrogen receptor: a mimic of carcinoma and a potential diagnostic pitfall. <i>Journal of Cutaneous Pathology</i> , 2011, 38, no-no.	1.3	7
113	Anaplastic Oligodendroglioma Involving the Subcutaneous Tissue of the Scalp. <i>American Journal of Dermatopathology</i> , 2012, 34, 214-219.	0.6	7
114	Primary Cutaneous Gamma-Delta (γ/δ) T-cell Lymphoma: An Unusual Case With Very Subtle Histopathological Findings. <i>American Journal of Dermatopathology</i> , 2016, 38, e147-e149.	0.6	7
115	Cutaneous histoplasmosis with prominent parasitization of epidermal keratinocytes: report of a case. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 1155-1160.	1.3	7
116	The utility of digital pathology in improving the diagnostic skills of pathology trainees in commonly encountered pigmented cutaneous lesions during the COVID-19 pandemic: A single academic institution experience. <i>Annals of Diagnostic Pathology</i> , 2021, 54, 151807.	1.3	7
117	Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 472-481.	1.3	7
118	The utility of ATF3 in distinguishing cutaneous squamous cell carcinoma among other cutaneous epithelial neoplasms. <i>Journal of Cutaneous Pathology</i> , 2012, 39, 762-768.	1.3	6
119	Coccidioidomycosis Involving Lungs and Skin: A Mimicker of Metastatic Disease. <i>American Journal of Dermatopathology</i> , 2018, 40, e41-e43.	0.6	6
120	Diagnosis of T-cell lymphoid proliferations of the skin: putting all the pieces together. <i>Modern Pathology</i> , 2020, 33, 83-95.	5.5	6
121	Correlative study of epigenetic regulation of tumor microenvironment in spindle cell melanomas and cutaneous malignant peripheral nerve sheath tumors. <i>Scientific Reports</i> , 2020, 10, 12996.	3.3	6
122	TERT amplification but not activation of canonical Wnt/ β -catenin pathway is involved in acral lentiginous melanoma progression to metastasis. <i>Modern Pathology</i> , 2020, 33, 2067-2074.	5.5	6
123	Cutaneous balamuthiasis: A clinicopathological study. <i>JAAD International</i> , 2022, 6, 51-58.	2.2	6
124	Changes in Tumor Morphology and Cyclin-Dependent Kinase Inhibitor Expression in Metastatic Melanoma Treated With Selective Second-Generation BRAF Inhibitor. <i>American Journal of Dermatopathology</i> , 2013, 35, 125-128.	0.6	5
125	Isolated Ectopic Cutaneous Atypical Meningioma of the Scalp: Another Mimicker of Primary Adnexal Tumor. <i>American Journal of Dermatopathology</i> , 2017, 39, 545-547.	0.6	5
126	Intraepithelial Melanoma in the Stomach After Treatment With Immune Checkpoint Blockade Therapy. <i>American Journal of Dermatopathology</i> , 2017, 39, e116-e118.	0.6	5

#	ARTICLE	IF	CITATIONS
127	Aberrant expression of <sc>FLI</sc> in melanoma. Journal of Cutaneous Pathology, 2017, 44, 790-793.	1.3	5
128	Metastatic melanoma with balloon/histiocytoid cytomorphology after treatment with immunotherapy: A histologic mimic and diagnostic pitfall. Journal of Cutaneous Pathology, 2018, 45, 545-549.	1.3	5
129	Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course?. Leukemia and Lymphoma, 2018, 59, 1753-1755.	1.3	5
130	Angiotropism in recurrent cutaneous squamous cell carcinoma: Implications for regional tumor recurrence and extravascular migratory spread. Journal of Cutaneous Pathology, 2018, 46, 152-158.	1.3	5
131	Immunohistochemical and Molecular Features of Melanomas Exhibiting Intratumor and Intertumor Histomorphologic Heterogeneity. Cancers, 2019, 11, 1714.	3.7	5
132	Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment. JAAD Case Reports, 2020, 6, 1264-1267.	0.8	5
133	Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 377-383.	2.8	5
134	Diverse landscape of dermatologic toxicities from smallâ€molecule inhibitor cancer therapy. Journal of Cutaneous Pathology, 2022, 49, 61-81.	1.3	5
135	Role of Radiotherapy in Aggressive Digital Papillary Adenocarcinoma. Annals of Clinical and Laboratory Science, 2016, 46, 222-4.	0.2	5
136	An unusual case of cytotoxic peripheral T-cell lymphoma. JAAD Case Reports, 2015, 1, 257-260.	0.8	4
137	Chronic granulomatous reaction in patients receiving vaccine immunotherapy for metastatic melanoma. JAAD Case Reports, 2018, 4, 87-90.	0.8	4
138	Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immuneâ€related adverse event with mycosisâ€fungoidesâ€like morphologic and molecular features. Journal of Cutaneous Pathology, 2019, 46, 872-877.	1.3	4
139	Primary cutaneous CD4+ smallâ€to mediumâ€sized pleomorphic Tâ€cell lymphoproliferative disorder in a pediatric patient successfully treated with lowâ€dose radiation. Pediatric Dermatology, 2019, 36, e23-e26.	0.9	4
140	Lichen planus related to transforming growth factor beta inhibitor in a patient with metastatic chondrosarcoma: a case report. Journal of Cutaneous Pathology, 2020, 47, 490-493.	1.3	4
141	Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response. Journal of Cutaneous Pathology, 2021, 48, 674-679.	1.3	4
142	Localized cutaneous argyria: Review of a rare clinical mimicker of melanocytic lesions. Annals of Diagnostic Pathology, 2021, 54, 151776.	1.3	4
143	Enhanced T-Cell Priming and Improved Anti-Tumor Immunity through Lymphatic Delivery of Checkpoint Blockade Immunotherapy. Cancers, 2022, 14, 1823.	3.7	4
144	Treatment With Dupilumab for Refractory Cutaneous B-Cell Pseudolymphoma. JAMA Dermatology, 2022, 158, 697.	4.1	4

#	ARTICLE	IF	CITATIONS
145	Primary Cutaneous CD8+ T-cell Lymphoma Masquerading as Acral Vascular Syndrome. <i>Acta Dermato-Venereologica</i> , 2014, 94, 317-319.	1.3	3
146	Extranodal Marginal Zone Lymphoma From Ocular Adnexae With Subcutaneous Involvement. <i>American Journal of Dermatopathology</i> , 2014, 36, e189-e193.	0.6	3
147	Metastatic Melanoma With Papillary Features: A Mimic and Possible Diagnostic Pitfall. <i>American Journal of Dermatopathology</i> , 2017, 39, 468-470.	0.6	3
148	Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers. <i>Annals of Diagnostic Pathology</i> , 2018, 34, 151-154.	1.3	3
149	Melanoma coexisting with solar elastosis: a potential pitfall in the differential diagnosis between nevus and melanoma. <i>Human Pathology</i> , 2019, 84, 270-274.	2.0	3
150	Langerhans cell sarcoma involving skin and showing epidermotropism: A comprehensive review. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 547-557.	1.3	3
151	Molecular characterization of biphenotypic epithelioid and plexiform melanoma with deep penetrating nevus-like features. <i>Pigment Cell and Melanoma Research</i> , 2021, , .	3.3	3
152	Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 1911-1924.	7.0	3
153	Resistant mechanisms to BRAF inhibitor PLX4032 in melanoma. <i>Expert Review of Dermatology</i> , 2011, 6, 355-357.	0.3	2
154	Dermal xanthomatous infiltrates after brentuximab vedotin therapy in mycosis fungoides with large-cell transformation: A novel histologic finding. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 711-715.	1.3	2
155	Cutaneous neoplasms composed of melanoma and carcinoma: A rare but important diagnostic pitfall and review of the literature. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 36-46.	1.3	2
156	Lymphomatoid Papulosis With a Unique T Follicular Helper-Like Phenotype. <i>American Journal of Dermatopathology</i> , 2020, 42, 776-779.	0.6	2
157	Cutaneous Lymphoid Hyperplasia With T-Cell Clonality and Monotypic Plasma Cells Secondary to a Tick Bite: A Hidden Critter and the Power of Deeper Levels. <i>American Journal of Dermatopathology</i> , 2022, 44, 226-229.	0.6	2
158	Hematolymphoid Proliferations of the Skin. <i>Molecular Pathology Library</i> , 2015, , 3-36.	0.1	2
159	Multimodality Imaging and Genetics of Primary Mucosal Melanomas and Response to Treatment. <i>Radiographics</i> , 2021, 41, 1954-1972.	3.3	2
160	The dilemma of primary epidermotropic T-cell lymphoma: Distinction from mycosis fungoides, signs of cytotoxicity, and need for more detailed analysis. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 419-420.	1.3	2
161	Ganglion cyst in a 52-year-old man with metastatic melanoma. <i>Diagnostic Cytopathology</i> , 2006, 34, 485-485.	1.0	1
162	Novel Intra-Adrenal Secondary Lymphoid Follicle Formation. <i>Endocrine Pathology</i> , 2013, 24, 248-249.	9.0	1

#	ARTICLE	IF	CITATIONS
163	From mycosis fungoides to herpetic folliculitis: The significance of deeper H&E tissue sections in dermatopathology. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 624-626.	1.3	1
164	Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall. <i>Journal of Dermatology</i> , 2020, 47, e354-e355.	1.2	1
165	Cutaneous adnexal carcinosarcoma: Immunohistochemical and molecular evidence of epithelial mesenchymal transition. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 526-534.	1.3	1
166	Aggressive primary cutaneous anaplastic large cell lymphoma with massive bilateral upper limb involvement at relapse. <i>JAAD Case Reports</i> , 2021, 17, 34-37.	0.8	1
167	Dermatologic Toxicities to Melanoma Targeted Therapies. , 2016, , 267-277.		1
168	Eosinophilic homogeneous intracytoplasmic inclusion bodies: Unique viral cytopathic changes associated with epidermodysplasia verruciformis and human papillomavirus type 49. <i>Journal of Cutaneous Pathology</i> , 2022, , .	1.3	1
169	Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 842-850.	2.5	0
170	Infectious Diseases of the Skin. <i>Molecular Pathology Library</i> , 2015, , 81-102.	0.1	0
171	Biomarker Analysis of Gene-Mutated Protein Products by Immunohistochemistry in Melanoma. , 2016, , 181-191.		0
172	Immunohistology and Molecular Studies of Cutaneous T-Cell Lymphomas and Mimics. , 2016, , 229-259.		0
173	Immunohistology of Melanocytic Lesions. , 2016, , 311-334.		0
174	Primary cutaneous Epstein-Barr virus-positive B-cell lymphoid proliferation with features of diffuse large B-cell lymphoma and mucocutaneous ulcer: a diagnostic dilemma. <i>International Journal of Dermatology</i> , 2022, , .	1.0	0